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In Ph-positive (Ph
þ) leukemia, the quiescent cell state is one of
the reasons for resistance to the BCR-ABL-kinase inhibitor,
imatinib. In order to examine the mechanisms of resistance
due to quiescence and the effect of the mammalian target of
rapamycin inhibitor, everolimus, for such a resistant popula-
tion, we used Ph
þ acute lymphoblastic leukemia patient cells
serially xenotransplanted into NOD/SCID/IL2rc
null (NOG) mice.
Spleen cells from leukemic mice showed a higher percentage of
slow-cycling G0 cells in the CD34
þCD38
  population compared
with the CD34
þCD38
þ and CD34
  populations. After
ex vivo imatinib treatment, more residual cells were observed
in the CD34
þCD38
  population than in the other populations.
Although slow-cycling G0 cells were insensitive to imatinib in
spite of BCR-ABL and CrkL dephosphorylation, combination
treatment with everolimus induced substantial cell death,
including that of the CD34
þCD38
  population, with p70-S6K
dephosphorylation and decrease of MCL-1 expression. The
leukemic non-obese diabetic/severe combined immunodeﬁ-
ciency (NOD/SCID) mouse system with the in vivo combination
treatment with imatinib and everolimus showed a decrease of
tumor burden including CD34
þ cells. These results imply that
treatment with everolimus can overcome resistance to imatinib
in Ph
þ leukemia due to quiescence.
Blood Cancer Journal (2011) 1, e17; doi:10.1038/bcj.2011.16;
published online 13 May 2011
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Introduction
Marked clinical improvement was reported when a BCR-ABL-
kinase inhibitor, imatinib, was combined with chemotherapy for
the treatment of Ph-positive (Ph
þ) acute lymphoblastic leuke-
mia (ALL).
1,2 However, further improvement is needed to
decrease relapses owing to residual or resistant leukemic cells.
Leukemia stem cells (LSCs) are reported to be responsible for
leukemia relapse.
3 Mathematical models of the chronic phase of
chronic myeloid leukemia suggested that imatinib does not
eradicate LSCs,
4,5 and the survival of malignant cells is
reportedly attributable to the quiescence of LSCs.
6
In order to overcome drug resistance, rational combinations
of molecular targeting drugs of different signal pathways
have been explored.
7 The mammalian target of rapamycin
(mTOR) has attracted attention as a therapeutic target of LSCs.
8,9
mTOR regulates cell growth and apoptosis through the
phosphatidilinositide-3-kinase (PI3K)/AKT/mTOR pathway, which
was reported to be constitutively activated in most AMLs
10 or in
T-ALL cell lines.
11 The inhibitory effect of an mTOR inhibitor,
rapamycin, on the Ph
þ leukemia cell lines with T315I was
reported,
7 and more recently, the effect of everolimus (RAD001)
on human childhood B-cell progenitor ALL was reported in a
non-obese diabetic/severe combined immunodeﬁciency (NOD/
SCID) model.
12 The mTOR inhibitor everolimus is an orally
available mTOR inhibitor which was approved by the Food and
Drug Administration for advanced renal cell carcinoma. A phase
I/II study has been performed in patients with acute leukemia,
13
and clinical trials alone or in combination with other drugs are
also currently ongoing for lymphoma and myeloma.
14 Effects of
everolimus on human Ph
þ ALL have not been well examined.
In this study, we examined the efﬁcacy of everolimus in
combination with imatinib utilizing Ph
þ ALL cell lines and an
NOD/SCID/IL2rg
null (NOG) mouse model of human BCR-ABL
þ
leukemia,
15 in which the hierarchy of leukemia cells was
maintained.
Materials and methods
Leukemic cells
Xenografts were established in NOD/SCID/IL2rg
null (NOG) mice
as previously described.
15 Brieﬂy, Ph
þ ALL patient cells were
serially xenotransplanted into immunodeﬁcient NOG mice, and
engrafted spleen cells were obtained 8–10 weeks after injection.
Erythrocytes were removed by erythrocyte lysis buffer (EL-buffer;
Qiagen, Hilden, Germany), and the remaining leukemic cells
were preserved in liquid nitrogen until use. Leukemic repopu-
lated cells were thawed and washed, resuspended in RPMI
containing 10% fetal bovine serum, 5mM MgCl2 and 0.2mg/ml
DNase I (Roche Diagnostics, Mannheim, Germany) and
incubated at 371C for 10min. Cells were washed and
resuspended at 1 million cells per ml in RPMI containing 20%
fetal bovine serum with cytokines (human stem cell factor,
50ng/ml, human interleukin-3 20ng/ml and human granulo-
cyte/macrophage-colony-stimulating factor, 20ng/ml), and
incubated with imatinib for 48h at 371Ci naC O 2 incubator.
In an in vitro long-term culture, spleen (SP) cells derived from
leukemic NOG mice were co-cultured with S17 stromal cells
and treated with imatinib and everolimus.
16 S-17 cells and
leukemic cells were passaged twice weekly.
Reagents
Everolimus and imatinib were supplied by Novartis Institutes
for Biomedical Research (Basel, Switzerland). Imatinib was
dissolved in dH2O and used for in vitro and in vivo experiments.
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 2M stock solution in dimethylsulf-
oxide for an in vitro experiment. For in vivo experiments,
everolimus was formulated at 2% (wt/wt) in a microemulsion
vehicle. Aliquots of everolimus and control vehicle were stored
at  201C.
Immunoblotting
Antibodies against the phospho(p)-Abl (Tyr245), p-CrkL
(Tyr207), p-mTOR (Ser2448), p-p70 S6 kinase (Thr389),
p-4EBP1 (Thr37/46), MCL-1, p-AKT (Ser473), AKT and
p-FOXO1(Thr24)/FoxO3a(Thr32) were from Cell Signaling
(Boston, MA, USA). Immunoblotting was performed with the
standard protocols as previously described.
17
Flow cytometric analysis and cell sorting
After the treatment period, cells were washed at 41C and then
stained with anti-CD34-allophycocyanin (APC), anti-CD38-PE-
Cy7 (Becton Dickinson, San Jose, CA, USA), and anti-CD45-
APC-Alexa Fluor 750 (Invitrogen, Carlsbad, CA, USA) antibodies
(1:100) for 30min on ice. Cells were subsequently labeled with
annexin-V-ﬂuorescein isothiocyanate and propidium iodide (PI)
according to the manufacturer’s protocol (Annexin-V-FLUOS
Staining Kit; Roche Diagnostics). The cells were acquired by
FACS Aria (Becton Dickinson) and analyzed by Flow Jo
software. DNA contents analysis was assessed using the
standard procedure as previously described.
18 For CD34
þ
selection, leukemic cells were subjected to immunomagnetic
separation using a MACS CD34 MicroBead Kit (Miltenyi
Biotech, Auburn, CA, USA) following the manufacturer’s
recommendations. The collected cells were applied to a second
column and the puriﬁcation step was repeated. Staining of cells
with Hoechst 33342 (Sigma, St Louis, MO, USA) with PyroninY
(Polysciences, Warrington, PA, USA) was performed as pre-
viously described.
19 Brieﬂy, thawed leukemic spleen cells were
separated with the MACS CD34 MicroBead Kit (Miltenyi
Biotech) into CD34
þ cells and ﬂow-through cells containing
CD34
  cells. MACS-separated cells or drug-treated cells on S17
were washed and stained with Hoechst 33342 and PyroninY,
and washed at 41C. MACS-separated CD34
þ cells were then
stained with anti-CD38-APC, and ﬂow-through cells containing
CD34
  cells were stained with anti-CD34-APC. Flow cyto-
metric analysis was performed using FACS Aria.
For cell sorting, leukemic spleen cells were stained with
anti-CD34-APC, anti-CD38-PE-Cy7 and anti-CD45-APC-Cy7
antibodies and labeled with PI. PI
  CD45
þ cells were sorted
for CD34 and CD38 expression using FACS Aria, incubated with
treatment drugs for 6h at 371Ci naC O 2 incubator as described
above.
Mouse models
Humanized leukemic mouse model. NOG and NOD/SCID
mice were obtained from the Central Institute for Experimental
Animals (Kawasaki, Japan) and Clea Japan (Tokyo, Japan),
respectively. Seven-week-old male NOD/SCID mice received
2Gy of total body irradiation from an X-ray source (MBR-1520R-
3; Hitachi Medico Technology Corporation, Tokyo, Japan),
24h before administration of leukemic 2 10
7 cells. Everolimus
(5mg/kg), imatinib (100mg/kg) or vehicle were diluted with dH2O,
and given daily at 10ml/kg for 10 days by gavage. Bone marrow
and spleen cells were stained with anti-human CD19-PE (Becton
Dickinson) and anti-mouse CD45-PerCP, and acquired with
FACS Aria to analyze chimerism. Cells were also stained with
anti-CD34-APC, anti-CD38-PE-Cy7 and anti-CD45-APC-Alexa
Fluor 750, and were subsequently labeled with annexin-V–
ﬂuorescein isothiocyanate and PI as explained above. Protocols
were approved by the Nagoya University Animal Ethics
Committee.
Histopathology
Livers, spleens and femurs were ﬁxed in 15% buffered formalin.
Hematoxylin and eosin, and CD34 staining were performed as
previously described.
20–22 Slides were examined at room
temperature and images were captured by a ﬂuorescence
microscope with a charge-coupled device camera (BZ-8000;
Keyence, Osaka, Japan) ﬁtted with  20 and  60 objective.
Images were acquired by BZ-analyzer software (Keyence).
Statistical analysis
Differences among more than two groups were analyzed with
the Bonferroni test followed by one-way analysis of variance.
Statistical analyses were performed with STATA 9.2 software
(StataCorp, College Station, TX, USA).
Results
Ex vivo treatment with imatinib for more residual
quiescent CD34
þCD38
  population in Ph
þ ALL cells
We analyzed the cell cycle status of untreated spleen cells
derived from the humanized Ph
þ ALL leukemia murine model
reported previously.
15 In the CD34
þCD38
  population, a
higher percentage of Hoechst
low/PyroninY
low slow-cycling
quiescent cells was observed than in the CD34
þCD38
þ
population (Po0.05) and CD34
  population (Po0.01). A lower
percentage of the SþG2/M population was also observed
among CD34
þCD38
  cells (Po0.05; Figure 1a, Supplementary
Figure S1a).
We next treated these cells with imatinib for 48h and
analyzed the distribution of CD34/CD38 in residual viable cells.
After treatment with imatinib at 0.3, 1 and 3mM, more residual
CD34
þCD38
  cells were observed than non-treated cells (12.8
vs 27.2%; Figure 1b, Po0.05; Supplementary Figure S1b).
Signiﬁcantly more slow-cycling quiescent (G0) cells were
observed within CD34
þ38
  population after treated with 3mM
of imatinib (P¼0.03), and less G0 cells in CD34
  population
(P¼0.02, Figure 1c).
Treatment of CD34/CD38 sorted cells for 6h with 3mM imatinib
caused equivalent inhibition of the phosphorylation of BCR-ABL
and direct-substrate CrkL in each CD34/CD38 sub-population
(Figure 1d). Inhibition of phosphorylation with imatinib (1 and
3.3mM) was also observed with intracellular staining of phospho-
CrkL (Supplementary Figure S1c). Expressions of BCR-ABL and
ABL were equivalent in each CD34/CD38 sub-population
(Figure 1d). These results suggested that the slow-cycling
population derived from Ph
þ leukemia NOG mice was
insensitive to imatinib in spite of BCR-ABL dephosphorylation.
Ex vivo effects of everolimus on leukemic spleen cells,
alone and in combination with imatinib
Furthermore, we have introduced S-17 murine stromal cell lines
to support the leukemic spleen cells in order to assess longer-
term effect of treatment drugs,
16 as the CD34
þ population of
leukemic cells from the NOG mice eventually differentiated into
CD34
  cells and could not be maintained only with cytokines
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Blood Cancer Journalfor a longer period. If cultured with S17 cells, leukemic spleen
cells were viable for more than 30 days (Figure 2a).
To examine the potential of everolimus to overcome
resistance due to quiescence in Ph
þ leukemia cells, everolimus
treatment was investigated ex vivo alone and in combination
with imatinib on S17 stromal cells. Everolimus treatment at
100nM for 5 days increased the sub-G1 population (14 vs 7.9%;
control), and combination of everolimus (100nM) and imatinib
(1mM) further increased the sub-G1 population (68%, Figure 2b,
upper panel). Cell cycle status was also investigated after
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Figure 1 Ex vivo analysis of humanized mouse positive (Ph
þ) acute lymphoblastic leukemia cells. (a) Leukemic spleen cells were CD34
positively selected with MACS column. CD34
þ cells were stained with Hoechst, PyroninY and CD38-allophycocyanin (APC). Cells including
CD34
  population that had ﬂowed through the column were stained with Hoechst, PyroninY and CD34-APC. (b) Leukemic spleen cells were ex
vivo cultured with cytokines and treated with or without imatinib (IM) for 48h. Human CD45
þ propidium iodide (PI)
  Annexin-V
  viable
population was analyzed for CD34 and CD38 distribution. Panels show a representative experiment. (c) After treated with IM for 48h, CD34
þ
cells were positively selected with MACS column, and stained with Hoechst, PyroninY and CD38-APC. Cells including CD34
  population that
had ﬂowed through the column were stained with Hoechst, PyroninY and CD34-APC. Graphs show the number of forward scatter/side scatter
gated G0 cells in each CD34/CD38 sub-population, each relative to the untreated control. Bars indicate mean±s.d. values of three independent
experiments (*P¼0.03 between control and IM 3mM for CD34
þ CD38
 , and **P¼0.02 between control and IM 3mM for CD34
 , by one-way
analysis of variance followed by Bonferroni). (d) CD34/CD38 sorted populations were treated with or without IM 3mM for 6h. Expression of BCR-
ABL and phosphorylation of BCR-ABL and CrkL in each population was examined by western blotting analysis.
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and imatinib-treated cells showed 35% of Hoechst
low/PyroninY
low
cells in total acquired cells, combination of imatinib and
everolimus decreased these quiescent cells to 13% of total
acquired cells (Figure 2b, lower panels). Signiﬁcant difference
was found between imatinib alone and combination of
imatinib plus everolimus (Figure 2c). Treatment with everolimus
and imatinib for 5 days induced substantial cell death in
CD34
þ38
  population relative to dimethylsulfoxide control
(Figure 2d, Supplementary Figure S1d). These results indicated
that ex vivo combination treatment with imatinib and ever-
olimus was also effective for the quiescent CD34
þ38
  cells.
Evaluation of molecular biomarkers during cell death
induced by treatment with imatinib and everolimus
We next investigated the effects of imatinib and everolimus on
BCR-ABL and mTOR signaling. Separated CD34
þ cells were
treated with and without imatinib (1mM) or everolimus (100nM)
for 4h. After imatinib treatment, phosphorylation of BCR-ABL
was clearly inhibited in each population, but it was not affected
after everolimus treatment (Figure 3a). After everolimus treat-
ment, the phosphorylation of S6K, which is a direct substrate of
mTOR, was clearly inhibited; however, the phosphorylation of
mTOR and 4EBP1 was not changed (Figure 3b). These results
imply that everolimus inhibited mTOR signaling of CD34
þ cells
and induced cell death independently of the BCR-ABL signaling
pathway. Both imatinib alone and in combined treatment
inhibited phosphorylation of BCR-ABL. Conversely, everolimus
alone and in combination both inhibited phosphorylation of
S6K in both CD34
þ38
  and CD34
þ38
þ sub-populations
(Figure 3c). Everolimus alone or in combination with imatinib
decreased the expression of the antiapoptotic BCL-2 family
protein, MCL-1, after 4h, and the combination of everolimus
and imatinib also decreased the expression of MCL-1, not
BCL-2, after 12h (Figure 3c). These results implied that
combination treatment with imatinib and everolimus induced
cell death in quiescent Ph
þ leukemia cells.
In vivo investigation of effects of everolimus, alone
and in combination with imatinib
To elucidate the in vivo efﬁcacy of everolimus treatment, its
effects were investigated alone (5mg/kg) and in combination
with imatinib (100mg/kgþeverolimus 5mg/kg) using NOD/SCID
mice intravenously injected with leukemic spleen cells from
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Figure 2 Ex vivo effects of everolimus on leukemic spleen cells in combination with imatinib (IM). (a) Leukemic spleen cells were co-cultured
with S-17 stromal cells for up to 35 days. Cells were counted with Trypan blue, and viable cells were maintained. (b) Cells were treated with or
without everolimus (Eve, 100nM) and imatinib (1mM) alone and in combination for 5 days on S-17 cells. DNA contents were assessed (upper
panels) and Hoechst/PyroninY cell cycle analysis (lower panels) was performed. (c) Percentages of G0 population in total acquired cells were
compared with dimethylsulfoxide (DMSO) control after 5-day treatment with imatinib (1mM), everolimus (100nM) or in combination. Graph shows
the means±s.d. values of three independent experiments (*Po0.05 by one-way analysis of variance followed by Bonferroni). (d) In the stromal-
culturing system, leukemic spleen cells were treated with DMSO (upper column) or in combination of imatinib and everolimus (lower column) for
5 days. Cells were stained with CD34, CD38, human CD45, propidium iodide, and Annexin-V. Cells were gated for human CD45
þ and CD34/
CD38, and cell viabilities in CD34
þ38
  population are shown. Panels show a representative analysis.
Everolimus overcomes resistance in quiescent Ph
þ leukemia cells
Y Kuwatsuka et al
4
Blood Cancer Journalhumanized NOG mouse (Figure 4a). Percentage of CD19
þ
leukemic cells in peripheral blood was lowest in the imatinib-
plus-everolimus-treated group, compared with the vehicle or
imatinib alone (Figure 4b). Overall tumor burden, as assessed by
spleen weight (Figure 4d) and the total number of splenic human
CD19
þ leukemic cells (Figure 4e), was observed to be lowest in
the imatinib-plus-everolimus-treated group. Immunohistochem-
istry showed that the combination of imatinib plus everolimus
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Figure 3 Western blot analysis of ex vivo-treated leukemic cells. (a) CD34
þ cells were separated with MACS column and cells were treated with
and without imatinib (IM, 3mM) or everolimus (Eve, 300nM) for 4h. Each sample was lysed and western blotting analysis was performed with each
antibody. (b) MACS-separated cells were treated with or without everolimus (100nM) for 4h. Each sample was lysed and western blotting was
performed with p-mTOR, p-S6K, p-4EBP1 antibodies. Immunoblotting by antitubulin was performed for the control. (c) CD34
þ38
  and
CD34
þ38
þ sorted cells were treated with treatment drugs for 4 or 12h. Each sample was lysed and western blotting analysis was performed with
each antibody.
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Figure 4 In vivo effects of everolimus on leukemic spleen cells in combination with imatinib. (a) Non-obese diabetic/severe combined
immunodeﬁciency ( mice were irradiated (IR), and leukemic spleen (SP) cells from NOG (2 10
7) were injected. Experiments were performed
twice with three in each treatment group. Control vehicle (n¼6), imatinib 100mg/kg (n¼6), everolimus 5mg/kg (n¼6) or a combination of both
(n¼6) were administered for 10 days, and mice were dissected 24h after the last administration on day 28 following the tumor injection. (b, c)
Percentages of CD19
þ cells in peripheral blood (b) and bone marrow (c) are shown, respectively. (d) Spleen weight was relatively compared with
the average of control mice in each experiment. Bars indicate average of spleen weight in each study group. (e) CD19
þ leukemic spleen cell
numbers were relatively compared with the average of control (b–e:* Po0.001, **Po0.005 and ***Po0.05 by one-way analysis of variance
followed by Bonferroni). (f) Hematoxylin and eosin (HE) staining (left panels) and immunohistochemical analysis with CD34 (right panels) of the
spleen from control mice and imatinib and/or everolimus-treated mice were performed. A charge-coupled device camera provided images at
approximately  100 of the original magniﬁcation.
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þ human leukemic cells in spleen,
liver and bone marrow (Figure 4f, Supplementary Figure S2).
Everolimus alone also decreased the percentage of G0 cells in the
CD34
þ leukemic cells of the treated bone marrow (Supplemen-
tary Figure S3). These results indicated the in vivo efﬁcacy of
everolimus treatment in a Ph
þ leukemia murine model.
Discussion
In this study, we showed the effects of everolimus in
combination with imatinib against Ph
þ ALL quiescent cells.
Ex vivo imatinib treatment of Ph
þ leukemia cells from a
humanized mouse model showed more residual cells in the
CD34
þCD38
  population, which contains signiﬁcantly more
quiescent cells. Our data showed an ex vivo effect against these
residual cells, and the combination of imatinib and everolimus
showed an in vivo effect. These data have shown the potential of
everolimus to overcome imatinib resistance in quiescent cells.
LSCs are reported to be responsible for the resistance to
chemotherapy and molecular targeting agents.
23,24 In chronic
myeloid leukemia, non-proliferating quiescent CD34
þ cells
have been found to be more resistant than proliferating leukemic
cells after treatment with several chemotherapeutic agents.
25
Other studies have shown that inhibitors of mTOR with
conventional therapies induced apoptosis and reduced LSCs.
8
The deﬁnition of LSCs or cancer stem cells is sometimes
controversial in certain diseases. In human AML, LSCs have
been phenotypically identiﬁed within a CD34
þCD38
  frac-
tion.
23,26 In contrast, it is controversial whether ALL LSCs exist
within the CD34
þ fraction and how CD34, CD38, CD19 and
CD133 relate to ALL LSCs.
15,27–29 In our current study, the
potential of everolimus to overcome imatinib-resistant quiescent
cells was demonstrated by using a humanized leukemic mouse
model that maintains the differentiation hierarchy of Ph
þ
leukemia.
15 However, it cannot be determined at this point if
the real LSCs of Ph
þ ALL can be diminished until the LSCs in
this disease category are clariﬁed.
MCL-1, an antiapoptotic member of the BCL-2 protein family,
reportedly regulates the self-renewal of human hematopoietic
stem cells as well as LSCs.
30 Mills et al.
31 also reported that
MCL-1 was translationally regulated by mTORC1. Together with
these reports, our results showing decreased expression of
MCL-1 by combination treatment of imatinib and everolimus
suggested that the combination treatment induced cell death of
quiescent Ph
þ leukemia cells by interfering with the mitochon-
drial-mediated cell death pathway. Rapamycin and its analogs
are also known to induce autophagic cell death,
32 and Bellodi
et al.
33 reported that target autophagy potentiates tyrosine
kinase-induced cell death in Ph
þ leukemia cells. We are also
investigating the relation of autophagy in cell death in our
experimental systems.
In this study, everolimus treatment of Ph
þ leukemia cells from
a humanized mouse model decreased the phosphorylation of
S6K, but it increased the phosphorylation of AKT (Ser473) and
FOXO1/3a (Supplementary Figure S4a). Rapamycin and its
analogs, such as everolimus and temsirolimus, are allosteric
mTOR inhibitors that function at a distance from the adenosine
triphosphate-catalytic binding site. Of the two cellular protein
complexes of mTOR molecule, mTORC1 and mTORC2,
mTORC1 is sensitive to these allosteric mTOR inhibitors and
mTORC2 is resistant.
34 mTORC2 directly activates AKT, and this
AKT activation in a feedback loop has been reported to correlate
with rapamycin failure.
35 This feedback loop might also be
related to our data on upregulated AKT.
Recently, a new generation of mTOR inhibitors has been
developed. Dual PI3K/mTOR inhibitors, such as BEZ235,
EX147 and PI-103, inhibit PI3K and both small molecules of
mTORC1/2.
36 Adenosine triphosphate-competitive mTOR
inhibitors that selectively inhibit TORC1/2 molecules also have
been reported to be effective against Ph
þ transformed leukemia
cells and to be less immunosuppressive than PI3K/mTOR
inhibitors.
37 The effectiveness of a new generation of mTOR
inhibitors should also be investigated in our future studies, in
particular, the efﬁcacy of these inhibitors against quiescent or
leukemic stem cells using a humanized leukemic mouse model.
However, it was suggested that dual PI3K/mTOR inhibitors may
cause a greater degree of immune suppression by affecting
normal cell functions.
14 Although we have examined the colony
formation of CD34
þ human umbilical cord blood and it was
suggested that everolimus did not severely interfere with
hematopoietic colony formation (data not shown), the effects
of everolimus and the new-generation mTOR inhibitors on
normal cells and immune functions must be investigated in
future studies.
Acquired mutation in the BCR-ABL gene also causes primary
and secondary treatment failure in Ph
þ leukemia. Our data
suggest that imatinib-resistant cell lines with T315I mutation
(Supplementary Figures S4b and c) can be inhibited with
everolimus with downregulation of the mTOR pathway (Sup-
plementary Figure S4d). The in vivo effect of everolimus on
T315I-mutated Ph
þ leukemic cells is also indicated (Supplemen-
tary Figure S4e). Further study is needed to determine the effect of
everolimus on T315I-mutated leukemia, especially in combination
with a T315I inhibitor such as AP24534 (ponatinib).
38
In conclusion, we have investigated the imatinib and ever-
olimus combination effect against human Ph
þ quiescent
leukemic cells utilizing a mouse model. Everolimus can improve
the treatment of resistant Ph
þ leukemia. These mice also provide
the opportunity to evaluate the effects of new therapeutic
modalities on leukemic cells in different stages of cell cycle.
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